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ABSTRACT
Nonselective T-cell depletion reduces the incidence of severe graft-versus-host disease after allogeneic
hematopoietic stem cell transplantation, but the cost is delayed and disordered antigen-specific immune
reconstitution and increased infection. We use a method of selective depletion of alloreactive T cells expressing
the activation marker CD69 after coculture with stimulator cells in a modified or standard mixed lymphocyte
reaction. The technique has been shown to reduce alloreactivity while retaining third-party responses in vitro
and, in a mismatched murine model, led to donor T-cell engraftment with a virtual absence of graft-versus-host
disease and increased survival. We show in a human HLA-mismatched and unrelated HLA-identical setting
that this technique retains >80% of specific cellular antiviral activity by cytomegalovirus-tetramer analysis and
cytomegalovirus/Epstein-Barr virus peptide-stimulated interferon- ELISpot assay. Furthermore, CD4
CD25 T-regulatory cells are not removed by this method of selective allodepletion and retain their function
in suppressing allogeneic proliferative responses. Preservation of antiviral cytotoxic T lymphocytes in selec-
tively allodepleted stem cell grafts would lead to improved antiviral immunity after transplantation. The
retention of immunosuppressive CD4 CD25 T-regulatory cells could lead to more ordered immune
reconstitution and further suppress alloreactive responses after transplantation.
© 2004 American Society for Blood and Marrow Transplantation
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lNTRODUCTION
Graft-versus-host disease (GVHD) is a cause of
ajor morbidity and mortality in allogeneic hemato-
oietic stem cell (AHSC) transplantation because of
he recognition by immunocompetent T cells within
he AHSC graft of nonself HLA or minor histocom-
atability antigens (mHags) present on recipient cells.
t has long been established that nonselective T-cell
epletion of the AHSC graft reduces the incidence of
evere GVHD in both the HLA-matched sibling and
LA-matched unrelated donor transplant setting and
ven with haploidentical transplants [1-3].
Although this maneuver leads to a reduction in
VHDmortality after transplantation, the removal of s
B&MTathogen-speciﬁc T cells leads to a delay in quantita-
ive and qualitative immune reconstitution [4]. This
ranslates into delayed recovery of antigen-speciﬁc
mmune responses in the recipient and an increase in
he incidence and severity of a broad spectrum of
nfections after transplantation.
Several methods of selective depletion of alloreac-
ive cells have been shown to be effective at reducing
he allogeneic response while maintaining third-party
eactivity. All rely on the stimulation of live responder
ells (from the donor cell pool) by irradiated stimula-
or (recipient) cells in a unidirectional mixed lympho-
yte reaction (MLR) or modiﬁed MLR (mMLR). Al-
oreactive responder cells may then be identiﬁed (and
ubsequently removed) by their expression of activa-
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2ion antigens—such as CD69 [5,6], CD25 [7-11], or
oth [12]—or destroyed by FAS-FAS ligand–medi-
ted apoptosis [13] or by photodynamic purging [14].
n vitro studies and murine models have been pub-
ished for all these techniques demonstrating effective
eduction of alloreactivity/GVHD.
Cytomegalovirus (CMV) infection after AHSC
ransplantation is a signiﬁcant cause of morbidity and
ortality and has a considerable economic effect [15].
signiﬁcant number of adults who receive AHSC
ransplants have had serologically detectable past ex-
osure to CMV. In the series of Meyer et al. [16] from
986, as many as 70% of CMV-seropositive transplant
ecipients developed clinically signiﬁcant CMV infec-
ion, and CMV disease was the most common cause of
eath in such patients. Prophylactic treatment with
anciclovir or acyclovir has only partially reduced
ost-AHSCT CMV infection and has the theoretical
isadvantage of selecting drug-resistant viral strains
17].
The strategy of monitoring patients for viral shed-
ing by the detection of viral genome by (real-time)
olymerase chain reaction reduces CMV infection and
eath in the ﬁrst 100 days after AHSCT but may have
he effect of postponing infection to a later stage after
ransplantation [18]. Such preemptive treatment is as-
ociated with adverse effects, especially (reversible)
eutropenia that often requires cessation of treatment.
he crucial importance of T cell–mediated immunity
n controlling CMV is underlined by the increased
ate of CMV infection seen in nonselective T cell–
epleted AHSCTs [19].
The cytotoxic T lymphocyte (CTL) response is of
ritical importance for control of CMV infection, and
t has been estimated that 1% to 5% of CTLs in
ealthy CMV-seropositive individuals have speciﬁcity
or CMV [20]. In controlling CMV disease, CTL
esponses are believed to be the main effector arms of
he adaptive immune system, although they are criti-
ally dependent on CD4 T-cell help [21]. In the
bsence of CD4 help, there may be persistence of
irus despite the presence of CD8 CMV-speciﬁc
TLs as the latter become anergic [22].
Nonselective T-cell depletion to reduce GVHD,
specially in the unrelated donor setting or in non-
dentical transplants, removes both CD8 CMV-spe-
iﬁc CTLs and CD4 CMV-speciﬁc T-helper cells
nd slows the recovery of CMV-speciﬁc immunity. A
ajor advantage of selective alloreactive cell depletion
s that it leaves the donor CD8 and CD4 T-cell
ool intact, and it has been shown to retain functional
nti-CMV activity in the HLA-mismatched setting
11]. Epstein-Barr virus (EBV)–driven posttransplan-
ation lymphoproliferative disorder (PTLD) is an-
ther cause of signiﬁcant morbidity and mortality af-
er AHSCT. EBV-speciﬁc CTL responses are of
aramount importance in PTLD, and infusion of very 1
60mall numbers of donor-derived EBV-speciﬁc CTLs
re very effective at suppressing PTLD. Selective al-
oreactive cell depletion may leave donor EBV-spe-
iﬁc CTLs intact in the donor cell pool and confer
ore active EBV immunity after AHSC transplanta-
ion.
CD4 CD25 T-regulatory cells, which form
ewer than 10% of resting human CD4 lymphocytes,
re now recognized as playing an important role in the
uppression of immune responses [23]. These cells are
equired for the ex vivo induction of tolerance to
lloantigen via co-stimulatory blockade and for the
nhibition of allogeneic skin graft rejection. There is
lso evidence that these cells can suppress the allo-
eactive response and limit the development of
VHD. Depletion of CD4 CD25 cells from the
onor T-cell inoculum or in vivo CD25 depletion of
he recipient before transplantation resulted in in-
reased GVHD mediated by CD4 or whole T cells
n mice. The infusion of freshly puriﬁed donor CD4
D25 cells modestly inhibited GVHD when admin-
stered in equal numbers with whole CD4 cells but at
igher levels signiﬁcantly inhibited rapidly lethal
VHD [24].
The kinetics of upregulation of CD69 expression
n alloantigen-activated lymphocytes have been de-
ermined, and in a unidirectional MLR, the maximal
xpression of CD69 occurs after 72 to 96 hours—
omewhat earlier than the maximal expression of
D25 [25]. CD69 is thus a suitable antigen to use to
electively deplete alloantigen-activated lymphocytes
hile maintaining maximal cell viability. CD69 has
een used to identify and immunomagnetically de-
lete alloreactive cells after mixed lymphocyte culture
ith irradiated recipient cells. An mMLR [26] with
ytokine pretreatment of stimulator cells has been
sed to increase their alloimmunogenicity and thus
aximize the activation of alloreactive cells in HLA-
atched donor/recipient pairs in vitro. After deple-
ion of alloreactive cells, the nonalloreactive cell frac-
ions showed signiﬁcantly reduced proliferative
esponses against the original matched stimulators and
ad preservation of responses to third-party stimula-
or cells [5].
This technique has also been tested in a com-
letely mismatched nonobese diabetic/severe com-
ined immunodeﬁcient murine model of aggressive
VHD. Murine recipients of infusions of nonma-
ipulated major histocompatability complex class I
nd class II mismatched donor T cells experienced a
apid onset of acute (and generally fatal) GVHD. This
odel is akin to aggressive transfusion-associated
VHD. Recipients of lymphocyte infusions depleted
f CD69 alloreactive donor cells ex vivo and moni-
ored for 10 weeks after infusion demonstrated signif-
cantly improved survival (71.4% compared with
2.5% in the nonmanipulated group) and the absence
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Bf clinical or histologic evidence of GVHD despite the
resence of circulating donor lymphocytes demon-
trated by ﬂow cytometry [6].
We have used the CD69-based selective allodeple-
ion technique to remove alloreactive cells from both
LA-identical unrelated donor/recipient pairs and to-
ally HLA-mismatched donor/recipient pairs in which
he donor was known to be CMV immunoglobulin
Ig)G positive. CMV-reactive T cells were enumer-
ted before and after selective allodepletion by CMV-
eptide speciﬁc interferon (IFN)- ELISpot assay and
y CMV-peptide HLA A0201 tetramer analysis.
BV-reactive T cells by IFN- ELISpot were also
numerated before and after selective alloreactive cell
epletion in the HLA-mismatched setting. CD4
D25 T-regulatory cell depletion should not occur
ith our CD69-based strategy, and to conﬁrm this, we
numerated and tested the functionality of CD4
D25 T-regulatory cells after CD69-based selective
llodepletion.
ATERIALS AND METHODS
HLA-A–, -B–, and -DR–identical unrelated do-
or/recipient pairs and complete HLA-A–, -B–, and
DR–mismatched donor/recipient pairs were chosen
ith donors seropositive for CMV IgG or EBV nu-
lear antigen IgG (Table 1). Written consent was
btained for the use of all blood samples. Peripheral
lood mononuclear cells (PBMCs) were obtained by
ensity gradient centrifugation (Lymphoprep; Ny-
omed-Amersham, Buckinghamshire, UK), and cells
ere used fresh or after storage in liquid nitrogen.
Alloreactivity was assessed by a primary unidirec-
ional MLR in an unmodiﬁed form in the HLA-
ismatched pairs. Irradiated (30-Gy) stimulators were
ocultured in RPMI 1640 supplemented with 10%
uman AB serum and 1% penicillin/streptomycin
complete media; all Gibco, Paisley, UK) with live
esponder cells in 96-well plates (Nunc, Rochester,
Y) with a stimulator-responder ratio of 1:1 at 37°C,
% CO2, and 60% humidity. After 108 hours, 1 Ci
f tritiated thymidine (Amersham, Buckinghamshire,
K) was added per 105 responder cells. The plates were
arvested at 120 hours on a harvester, and proliferative
lloreactive responses were measured as tritiated thy-
idine incorporation in responder cells by using a
eta-scintillation counter (Wallac, Turku, Finland).
In the HLA-matched unrelated donor/recipient
amples, the primary MLR was modiﬁed by pretreat-
ent of the stimulator cells with OKT3 or cytokines.
KT3 was obtained from a fermentation system by
sing a murine hybridoma–secreting human mito-
enic OKT3 (American Type Culture Collection cell
ine CRL-8001). The concentration of OKT3 in hy-
ridoma supernatant was quantiﬁed by murine IgG b
B&MTnzyme-linked immunosorbent assay, and 500 ng of
KT3 per well was immobilized on a 24-well plate by
vernight incubation at 4°C. Wells were then washed
wice, and 106 stimulator PBMCs were added per well
n complete media. The plates were incubated for 48
ours as described previously, and the cells washed
wice before use as stimulators in the MLR. No addi-
ional cytokines were added to the MLR in this strategy.
In the HLA-matched unrelated donor/recipient
amples, the primary MLR was alternately modiﬁed
y pretreatment of stimulator cells with recombinant
uman IFN- 1000 IU/106 cells and recombinant
uman tumor necrosis factor- 1000 IU/106 cells for
4 hours (R&D Systems, Abingdon, UK). Stimulator
ells were then diluted in complete medium and
ashed twice before use as stimulators in the MLR.
ecombinant human interleukin-4 (R&D Systems)
as added at a dose of 1000 IU/106 responder cells to
he MLR with this strategy. All experiments were
erformed in triplicate.
Selective allodepletion was achieved by perform-
ng a bulk MLR in the HLA-mismatched setting or a
ulk OKT3 and cytokine mMLR in the HLA-
atched setting by following the protocols outlined
reviously. However, after 72 hours of coculture, the
ells were sorted to deplete the responder cell fraction
f CD69 alloreactive cells. Depletion was achieved
able 1. HLA Typing of CMV IgG-Positive Responders in Sample
airs Used for Selective Depletion of Alloreactive Cells and Peptides
sed in CMV Peptide–Stimulated IFN- ELISpot Assays before and
fter Selective Depletion of Alloreactive Cells
Pair
Stimulator
(Recipient)
Responder
(Donor) HLA
Typing
CMV Peptide
Used in
IFN- ELISpot
1 HLA mismatched A3 B0702 TPRVTGGGAM
A26 B0801
2 HLA mismatched A0201 B0702 NLVPMVATV
A2402 B1401
3 HLA mismatched A0101 B0702 TPRVTGGGAM
A0101 B37
4 HLA mismatched A0201 B14 NLVPMVATV
A25 B58
5 HLA mismatched A0201 B44 NLVPMVATV
A74 B38
6 HLA mismatched A0201 N/A NLVPMVATV
7 HLA mismatched A0201 N/A NLVPMVATV
8 Matched at HLA-A,
-B, and -DR
A0101 B0801 DANDIYRIF
A0101 B0801
9 Matched at HLA-A,
-B, and -DR
A0201 B3501 NLVPMVATV
A0301 B3701
10 Matched at HLA-A,
-B, and -DR
A0101 B0702 TPRVTGGGAM
A0101 B37
11 Matched at HLA-A,
-B, and -DR
A0201 B0702 NLVPMVATV
A2402 B1401
12 Matched at HLA-A,
-B, and -DR
A0201 B4402 NLVPMVATV
A3101 B3503
/A indicates not assessed.y using CD69/ﬂuorescein isothiocyanate (FITC) an-
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2ibody (Becton Dickinson, Oxford, UK) and anti-
ITC microbeads with single use depletion columns
nd a magnetically activated cell sorter (Miltenyi Bio-
ech, Cologne, Germany). The depleted cell fraction
as used as the responder cell fraction in a secondary
LR to conﬁrm reduction in ﬁrst-party alloreactivity
nd preservation of third-party alloreactivity. The de-
letion efﬁciency (%) of CD69 cells was deﬁned as
% CD69 cells before depletion
% CD69 cells after depletion  100
% CD69 cells before depletion
CMV tetramer analysis was performed on unma-
ipulated PBMCs and on selectively allodepleted
BMCs on HLA-A0201–positive donors by using
phycoerythrin (PE)–conjugated HLA-A0201–re-
tricted human CMV AE42 peptide tetrameric con-
truct (a gift from the Anthony Nolan Research Insti-
ute, London, UK). A total of 1 g of tetramer was
ncubated with 106 cells for 30 minutes and then
ounterstained with CD3-allophycocyanin and CD8-
ITC (Becton Dickinson), and 104 events were ac-
uired on a FACSCalibur ﬂow cytometer (Becton
ickinson). Data were subsequently analyzed with
ellQuest Pro software (BD Biosciences).
A selection of HLA class I–restricted immuno-
enic human CMV virus peptides were used as stim-
latory peptides in an IFN- ELISpot assay
MabTech, Nacka, Sweden) by using polyvinylidene
iﬂuoride–lined 96-well plates (Millipore, Watford,
K). Peptides used were the A0201-restricted pp65
egmental-derived nonamer AE42 (NLVPMVATV),
he B0702-restricted decamer TPRVTGGGAM, and
he B0801-restricted nonamer DANDIYRIF (Proim-
une, Oxford UK) [27-29]. Peptides were stored at a
igh concentration in dimethyl sulfoxide at 70°C
nd diluted to 10 g/mL in complete media before use.
The HLA speciﬁcity of the AE42 peptide was
onﬁrmed before use in a T2-binding assay and was
lso shown to prevent the binding of PE-conjugated
LA-A0201–restricted human CMV AE42 peptide
etramer to the CD8 CTLs of a CMV IgG-positive
LA-A0201 subject (data not shown). Stimulatory
eptides were also tested in the IFN- ELISpot assay
n healthy CMV IgG-positive individuals of suitable
LA class I type. Brieﬂy, polyvinylidene diﬂuoride–
ined 96-well plated were washed with 70% ethanol,
nd a capture antibody was added at 1.5 g per well
nd incubated overnight at 4°C. After washing and
locking with RPMI 1640 containing 10% fetal calf
erum (FCS) (150 L per well) for 1 hour, cells were
ashed and live PBMCs were added (105 to 2  105
er well).
A total of 1 g of stimulatory peptide was used per
05 live responder cells incubated for 20 hours as
escribed previously. Cells were then removed and
ells washed before the addition of 100 L of diluted n
62iotinylated antibody in ﬁltered phosphate-buffered
aline (PBS) with 0.5% FCS to each well and incu-
ated for 90 minutes at room temperature. Wells were
hen washed 6 times with sterile, ﬁltered PBS. Then
00 L of streptavidin/alkaline phosphatase antibody
diluted 1:1000 in ﬁltered PBS/0.5% FCS) was added
o each well and incubated for 1 hour at room tem-
erature. Wells were washed 6 times with sterile ﬁl-
ered PBS, and 100 L of color change substrate
Bio-Rad, Hemel Hempsted, UK) was added per well.
lates were agitated gently at room temperature for
0 to 20 minutes until spots appeared. Color devel-
pment was stopped by washing in tap water 200 L
er well 3 times. Plates were left to air-dry at room
emperature overnight, and wells were photographed
ith an Olympus (Tokyo, Japan) digital camera and
issection microscope.
Negative controls were cells plus no peptide and
ells plus dummy (HLA-mismatched) peptide. Posi-
ive controls were cells stimulated with phytohemag-
lutinin (10 ng/106cells; Sigma-Aldrich, Dorset, UK).
ll experiments were performed in triplicate. ELISpot-
esponding cells were expressed as
Number of dots/well in test
 number of dots/well in controls
Number of cells/well
The frequency of CD3CD8 CMV-responding
ells was expressed as (% CD3CD8 PBMCs) 
umber of responding cells. The frequency of CMV-
eactive CD3 CD8 CTLs was determined in un-
anipulated donor samples and in selectively allode-
leted donor samples in both the HLA-matched and
LA-mismatched donor/recipient pairs.
A variety of EBV-derived peptides stimulate EBV-
TL responses. We chose to use the SVRDRLARL
eptide derived from the latent EBV nuclear antigen
A, which demonstrates immunodominance in HLA-
0201 individuals [30]. EBV-CTL activity was mea-
ured by peptide-stimulated IFN- ELISpot by using
he reagents and methodology for CMV peptide
LISpot outlined previously.
The frequency of CD4 CD25 T-regulatory
ells was measured before and after selective al-
odepletion by using CD25-PE and CD4-peridinin
hlorophyll-a protein antibodies (Becton Dickinson),
nd a FACSCalibur ﬂow cytometer was used for anal-
sis with CellQuest Pro software. After selective al-
odepletion, the CD69-depleted fraction was sorted
y ﬂow cytometry to select the CD4 CD25 T-
egulatory cell fraction. These sorted T-regulatory
ells were added at a ratio of 1:1 to an allogeneic
ismatched MLR with ﬁrst-party stimulators and re-
ponders autologous to the T-regulatory cells to assess
he immunosuppressive capacity of the T-regulatory
ells after selective allodepletion. The T-regulatory
egative fraction from the sort was also added to a
ﬁ
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Brst-party allogeneic MLR with responders autolo-
ous to the T-regulatory negative fraction as a nega-
ive control.
The unpaired t test with the Welch correction in
he presence of unequal variance and the paired t test
ere used as tests of statistical signiﬁcance, and a P
alue of	.05 was chosen to reject the null hypothesis.
ESULTS
llostimulation Was Effective and Allodepletion
as Efficient
In the HLA-mismatched pairs, CD69 was upregu-
ated on 5.9% 
 5% (mean 
 SD) of responder
D3 cells, 4.9% 
 2.3% of CD3 CD4 cells, and
.8% 
 4.2% of CD3 CD8 cells after allostimula-
ion in the standard MLR at 72 hours. The depletion
fﬁciency of these cells was 92% 
 7%, 91% 
 8%,
nd 85% 
 10%, respectively.
In the HLA-matched pairs, CD69 expression at 72
ours was not increased above autologous control in
he standard MLR (data not shown; P  .05). In
ontrast, allostimulation in the OKT3 mMLR led to
D69 expression on 20% 
 11% of CD3 responder
ells, 24% 
 15% of CD3 CD4 cells, and 15% 

% of CD3 CD8 cells at 72 hours. The time scale
f maximal responder CD69 expression was similar to
hat seen in HLA-mismatched pairs, although upregu-
ation of CD69 occurred somewhat earlier (data not
hown). The depletion efﬁciency of these cells was
2% 
 6%, 91% 
 8%, and 83% 
 14%, respec-
ively. In the same donor/recipient pairs, allostimula-
ion in the cytokine mMLR led to CD69 expression
n 7.2% 
 9% of CD3 responder cells, 8.3% 
 9%
f CD3 CD4 cells, and 5% 
 6% of CD3 CD8
ells at 72 hours. The time scale of maximal responder
D69 expression was similar to that seen in HLA-
ismatched pairs (data not shown). The depletion
fﬁciency of these cells was 86%
 16%, 86%
 15%,
nd 88% 
 12%, respectively. These results are sum-
arized in Table 2.
CD69 responses seen after allostimulation in
LA-matched pairs with both the OKT3 mMLR and
he cytokine mMLR were not signiﬁcantly different
able 2. CD69 Expression on Alloreactive Responder Cells and Depleti
LA-Matched OKT3 and Cytokine-Stimulated MLRs: Mean (SD)
Variable
HLA-Mismatched Pairs:
Standard MLR
CD3
CD3
CD4
CD3
CD8
Responder CD69* 5.9 (5) 4.9 (2) 4.8 (4)
D69 depletion efficiency 92 (7) 91 (8) 85 (10)
Above autologous control.rom those seen after stimulation with HLA-mis- t
B&MTatched third-party controls (data not shown). The
ield in all depletion procedures was 85% of viable
onalloreactive CD3 cells.
llodepletion Selectively Reduced First-Party
roliferation in MLRs
In HLA-mismatched donor/recipient pairs, the
rst-party alloreactivity in the secondary MLR assay
as reduced to 3.98% 
 4.5% of that seen in the
rimary MLR with retention of third-party prolifera-
ive responses (73.2% 
 24.3% of the predepletion
alue). In HLA-matched donor/recipient pairs, the
rst-party alloreactivity was reduced to 0.8% 
 0.9%
f the predepletion value after selective allodepletion
ith OKT3-pretreated stimulator cells, with retention
f third-party proliferative responses (58% of pre-
epletion values). In HLA-matched donor/recipient
airs, the ﬁrst-party alloreactivity was reduced to
.6% 
 4.4% of the predepletion value after selec-
ive allodepletion with cytokine-pretreated stimulator
ells, with retention of third-party proliferative re-
ponses (133% of predepletion values).
MV Tetramer-Positive Cells Were Retained
fter Selective Alloreactive Cell Depletion
HLA-A0201 restriction of the tetramer was dem-
nstrated by tetramer binding to CD3 CD8 cells in
n HLA-A0201 CMV IgG-positive subject but not in
n HLA-B0701 CMV IgG-positive subject. The
E42 peptide speciﬁcity was demonstrated by block-
ng of tetramer binding to CD3 CD8 cells in an
LA-A0201 CMV IgG-positive subject by treatment
f PBMCs with exogenous AE42 peptide in excess.
In HLA-mismatched donor/recipient pairs after
elective allodepletion, 93% 
 9% of CMV-AE42
eptide tetramer-positive CTLs were retained. In
LA-matched donor/recipient pairs after OKT3-
timulated MLR selective allodepletion, 88.5% 

6% of CMV-AE42 peptide tetramer-positive CTLs
ere retained, and after cytokine-stimulated MLR-
elective allodepletion, 87.0% 
 18.4% of CMV-
E42 peptide tetramer-positive CTLs were retained.
n example of AE42 peptide tetramer-positive CTL
reservation after HLA-matched selective allodeple-
iency of CD69 Cells in HLA-Mismatched Standard MLR and
HLA-Matched Pairs
OKT3 MLR Cytokine MLR

CD3
CD4
CD3
CD8 CD3
CD3
CD4
CD3
CD8
1) 24 (15) 15 (7) 7.2 (9) 8.3 (10) 5.0 (6)
) 91 (8) 83 (14) 86 (16) 86 (15) 88 (12)on Efﬁc
CD3
20 (1
92 (6ion is shown in Figure 1.
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2There was no signiﬁcant difference in paired
-tailed t test results between the frequency of CMV-
E42 peptide tetramer-binding CTLs before and af-
er selective allodepletion in the HLA-mismatched
onor/recipient pairs or in the HLA-matched pairs
electively allodepleted with either the OKT3-stimu-
ated MLR or the cytokine mMLR.
unctional CMV-Specific CTLs Were Retained
fter Selective Alloreactive Cell Depletion
The CMV peptides and ELISpot assays were op-
imized and validated in healthy CMV IgG-positive
ndividuals of known HLA class I types. The AE42
eptide was further validated in a T2-binding assay in
hich the addition of HLA-A0201–restricted peptide
o transporter-associated protein-deﬁcient HLA-
0201 T2 cells in culture resulted in stabilization and
n increase of expression of HLA-A0201 on the sur-
ace of T2 cells of 100% (whereas the addition of an
LA B0702-restricted CMV-peptide did not alter the
xpression of HLA-0201). The AE42 peptide also
ncreased CMV-speciﬁc CTL-mediated killing in a
ytotoxicity assay with T2 target cells (data not shown).
In HLA-mismatched donor/recipient pairs after
elective allodepletion, 89.2% 
 26.9% of the func-
ional CMV-reactive CTLs by IFN- ELISpot were
etained. In HLA-matched donor/recipient pairs af-
er OKT3-stimulated MLR-selective allodepletion,
2.3% 
 39.5% of the functional CMV-reactive
TLs by IFN- ELISpot were retained. In HLA-
atched donor/recipient pairs after cytokine-stimu-
ated MLR-selective allodepletion, 80.7% 
 17.9%
f the functional CMV-reactive CTLs by IFN-
LISpot were retained.
There was no signiﬁcant difference in a paired
-tailed t test between the frequency of functional
MV-reactive CTLs by IFN- ELISpot before and
igure 1. CMV CTLs are retained after CD69-based selective
D3 cells in an unmanipulated donor cell pool. b, HLA-A2 CMV
electively allodepleted fraction with OKT3-stimulated MLR. c, H
LA-matched selectively allodepleted fraction with cytokine-stimulfter selective allodepletion in the HLA-mismatched u
64onor/recipient pairs or in the HLA-matched pairs
electively allodepleted with either the OKT3-stimu-
ated MLR or the cytokine mMLR. Preservation of
oth the AE42 peptide tetramer-positive CTLs and
MV-reactive CTLs by IFN- ELISpot in both the
LA-mismatched and -matched setting is shown in
igure 2.
unctional EBV-Specific CTLs Were Retained
fter Selective Alloreactive Cell Depletion
Functional EBV-speciﬁc CTLs were measured by
FN- ELISpot in the HLA-mismatched setting. Af-
er selective allodepletion, there was no signiﬁcant
ifference in the number of EBV-reactive CTLs com-
ared with the predepletion samples (data not shown).
letion. a, HLA-A2 CMV AE42 (NLV) peptide tetramer-binding
(NLV) peptide tetramer-binding CD3 cells in an HLA-matched
CMV AE42 (NLV) peptide tetramer-binding CD3 cells in an
LR. (This ﬁgure show dot plots from a representative experiment.)
igure 2. Functional CMV CTLs are retained after CD69-based
elective allodepletion. Retention of CMVCTLs by HLA-A2 CMV
E42 (NLV) peptide tetramer and retention of functional CMV
TLs by CMV peptide–stimulated IFN- ELISpot after selective
llodepletion expressed as a percentage of the of value seen inallodep
AE42
LA-A2
ated Mnmanipulated cells.
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BD4 CD25 T-Regulatory Cells Were Retained
fter Selective Allodepletion
The level of CD4 CD25 T-regulatory cells
resent in the responder cell population after allo-
timulation at 72 hours was not signiﬁcantly altered
rom the baseline value in unmanipulated cells (CD4
D25 after allostimulation, 14.6% 
 7.9% versus
he baseline value, 17.9%
 1.0%; P .6) or from the
evel seen after autologous cell culture (CD4 CD25
fter allostimulation, 14.6% 
 7.9% versus autolo-
ous cell culture, 15.8% 
 9.7%; P  .9).
The level of CD4 CD25 T-regulatory cells
resent in the responder cell population after selective
llodepletion at 72 hours was not signiﬁcantly altered
rom the predepletion value (CD4 CD25 after al-
ostimulation, 14.6% 
 7.9% versus after depletion,
1.4% 
 2.2%; P  .54). In HLA-matched donor/
ecipient pairs, no difference in the levels of CD4
D25 T-regulatory cells was found either after al-
ostimulation or after selective allodepletion in either
he OKT3-stimulated MLR or the cytokine mMLR
epletion strategies (data not shown). In both the
LA-mismatched and -matched samples, CD69 se-
ective allodepletion removed a small fraction of
D25 cells that also expressed CD25; most of the
D4CD25 cells remained CD69 and were retained
n the selectively allodepleted fraction (Figure 3).
D4 CD25 T-Regulatory Cells Present in
electively Allodepleted Cell Fractions Retain
mmunosuppressive Function
CD4 CD25 T-regulatory cells sorted after se-
ective allodepletion retained their immunosuppres-
ive function by suppressing allogeneic MLR re-
ponses to ﬁrst-party stimulators. In the mismatched
etting, the mean ﬁrst-party allogeneic MLR response
igure 3. CD4 CD25 T-regulatory cells are not removed by CD
n HLA-matched samples leads to an appearance of both CD69 C
emoved by selective allodepletion based on CD69 expression. T-r
, Allostimulated responder cells; B, untreated responder cells; C,as signiﬁcantly reduced to 18.9% 
 9.4% of the n
B&MTontrol value by the addition of sorted selectively
llodepleted CD4 CD25 T-regulatory cells autol-
gous to and at equal numbers to the MLR responders
P  .005). Addition of autologous non–T-regulatory
ells from selectively allodepleted cell fractions in sim-
lar quantities did not signiﬁcantly alter the ﬁrst-party
llogeneic MLR response in this setting (Figure 4).
ective allodepletion. Allostimulation in the OKT3-stimulated MLR
and CD69 CD25 alloreactive CD3 CD4 T cells, which are
ry cells (CD4 CD25 CD69) are not removed by this process.
ely allodepleted responder cells.
igure 4. CD4 CD25 T-regulatory cells present in selectively
llodepleted cells retain immunosuppressive function. Proliferative
esponses to ﬁrst-party stimulators in HLA-mismatched allogeneic
LRs is signiﬁcantly reduced after the addition of CD4 CD25
-regulatory cells (autologous to the responders) from selectively
llodepleted cell fractions, whereas proliferation is not signiﬁcantly
ffected after the addition of the CD4 CD25 T-regulatory cell69 sel
D25
egulato
selectivegative fraction from selectively allodepleted cell fractions.
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2ISCUSSION
All modalities of selective alloreactive cell deple-
ion rely on the principle of stimulation of alloreactive
ells in a live responder (donor) cell population by
rradiated stimulator (recipient) cells in a unidirec-
ional mixed lymphocyte culture. In the HLA-A–,
B–, and -DR–identical setting, we used a technique of
retreatment of stimulator cells with mitogenic
KT3 to increase the capacity of the stimulator cell
ool (mixed PBMCs) to present alloantigens. Human
-cell clones have been shown to be capable of pre-
enting antigens [31]. Although the stimulation of T
ells with mitogenic OKT3 has been reported to lead
o anergy in responder cells when such T cells alone
re used as nonprofessional antigen-presenting cells in
he MLR [32], here we show that the HLA-matched
nrelated donor/recipient pairs tested demonstrated a
igniﬁcant upregulation of CD69 on responder cells
nd a signiﬁcant proliferative response in the OKT3-
timulated MLR with mixed PBMCs as stimulators
akin to that seen with the established cytokine
MLR). The stimulation and expansion of T-cell
timulator cells with mitogenic OKT3 has been de-
cribed recently as part of the protocol for clinical
cale application of a selective allodepletion technique
33]. Both this work and other work within our group
as shown that OKT3-treated/expanded T cells sig-
iﬁcantly upregulate molecules involved in alloanti-
en presentation, such as CD80 and CD86 [34]. Al-
hough it could be argued that important alloantigens
resented only by monocytes would be lost by the
xclusive use of T cells as APCs, our 48-hour pretreat-
ent of PBMCs with OKT3 retains a proportion
5%-10%) of monocytes within the APC pool. More-
ver, the use of predominantly T cells as APCs might
ead to retention of identiﬁed myeloid or B-cell–re-
tricted tumor-associated alloantigens [35-37] with
reservation of a graft-versus-leukemia effect.
In both the HLA-mismatched and -matched un-
elated donor/recipient pairs, immunomagnetic de-
letion of CD69 responder cells was efﬁcient and led
o a reduction in proliferation to the original stimu-
ators to 	5% of predepletion values and preservation
f proliferative responses to third-party controls.
ields of viable nonalloreactive T cells were com-
only 85% to 90%, meaning that the nonalloreactive
onor T-cell pool remains quantitatively intact with
his strategy. Depletion efﬁciency of alloreactive T
ells was greater than 90%, and residual CD69 cells
eft in responder cell pools only weakly expressed the
ntigen. If infused into the recipient, such cells might
till be capable of mounting an alloreactive response
nd causing GVHD, although if still bound to CD69
ntibody they might be easily destroyed by the recip-
ent’s reticuloendothelial system. In the published
onobese diabetic/severe combined immunodeﬁcient n
66ouse model of CD69-selective allodepletion, the de-
letion efﬁciency of 93% was sufﬁcient to completely
brogate GVHD in sublethally irradiated major his-
ocompatibility complex nonidentical mice [6]. How-
ver, the ability of small numbers of alloreactive cells
nfused to recipients in the context of the cytokine
elease that accompanies pretransplantation condi-
ioning remains a potential concern.
Responses to highly immunogenic HLA-disparate
ntigens might mask responses against minor histo-
ompatability antigens, which might stimulate re-
ponders more weakly or more slowly in the MLR.
he cytokine mMLR has been shown to be predictive
f clinical GVHD in HLA-identical AHSC transplant
ecipients after 120 hours of coculture, indicating that
lloresponders can proliferate to mHags in this time
cale [26]. Both the cytokine and the OKT3 pretreat-
ent strategy in the HLA-identical pairs we used led
o a maximal CD69 responder expression by 72 hours:
hus, alloresponses to mHags do not seem to be de-
ayed with respect to HLA-disparate antigens.
Greater than 80% of HLA-A0201 CMV AE42
eptide tetramer-reactive CTLs were retained in the
llodepleted fraction in both the HLA-mismatched
nd HLA-matched unrelated donor pairs. This is in
eeping with a recent study of CD25-based selective
llodepletion in HLA-mismatched pairs [11].
However, tetramer analysis gives no indication of
unctionality; tetramer-binding cells have been re-
orted without cytolytic function, especially in the
bsence of CD4 cell help [22]. Baseline levels of CMV
etramer-binding CTLs were 3- to 5-fold higher than
aseline CMV-reactive CTLs by IFN- ELISpot as-
ay, which is in keeping with published data [38].
Thus, the IFN- ELISpot assay, a functional test
f CMV reactivity, gives us important additional in-
ormation. We have shown that the great majority of
MV-reactive CTLs by IFN- ELISpot assay are
etained after selective allodepletion in the HLA-
atched setting with HLA-A0201, -B0702, and
B0801 responders, adding to published data using
ismatched pairs with HLA-A0201 responders [11].
The dominant CMV peptide response in every
ndividual can vary, even between individuals of the
ame HLA class I type [39], and thus additional CMV
esponses may have been retained that cannot be iden-
iﬁed by a single HLA-restricted peptide approach.
In the HLA-mismatched setting, we have shown
hat functional EBV immunity is preserved after se-
ective depletion of alloreactive cells. EBV and other
iruses that are controlled primarily by a T cell–
ediated immune response are important pathogens
fter AHSCT; these include respiratory syncytial virus
nd adenovirus [40-42]. Life-threatening complica-
ions arising from infection from all of these viruses
fter AHSCT have been treated successfully with do-
or lymphocyte infusions, with presumed transfer of
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Bntiviral CTLs [43-45]. Speciﬁc cellular antiviral im-
unity to such viruses might also be preserved by
elective alloreactive T-cell depletion of the donor
-cell pool.
Our data also demonstrate the quantitative pres-
rvation of CD4 CD25 T-regulatory cells after
elective allodepletion in both HLA-mismatched do-
or/recipient and matched unrelated donor/recipient
airs. Moreover, the functionality of such CD4
D25 T-regulatory cells was preserved after selec-
ive allodepletion, as demonstrated by retention of
heir immunosuppressive capability when added to
utologous live responder cells in an allogeneic MLR.
In common with CD69, expression of CD25 (the
ow-afﬁnity interleukin-2 receptor) is upregulated on
ctivated T cells. Alloreactive cells that upregulate
D69 after allostimulation come from both the CD8
nd CD4 subsets: some alloreactive cells express only
D69, some express only CD25, and some express
oth. It is possible that the CD25 cell population in
he allodepleted cell fractions contains some alloreac-
ive cells that have upregulated CD25 after presenta-
ion of alloantigens in the MLR. However, reduction
f ﬁrst-party proliferative responses after selective al-
odepletion to 	5% of their predepletion values indi-
ates that any CD69 CD25 cells that have upregu-
ated CD25 in response to alloantigens and remain
fter depletion are unable to make a signiﬁcant pro-
iferative response to ﬁrst-party stimulators and are
hus unlikely to contribute signiﬁcantly to in vivo
llogeneic responses. Puriﬁed CD4 CD25 cells
rom allodepleted cell fractions maintained the phe-
otype in vitro of T-regulatory cells [23] by reducing
roliferative responses to ﬁrst-party stimulators, and it
hus seems unlikely that any signiﬁcant population of
lloreactive cells had appeared within the CD4
D25 cell fraction or, if they had, that their re-
ponses were overwhelmed by the suppressive effects
f the true T-regulatory cells. Other markers of T-
egulatory cells are being identiﬁed (intracellular
D152 and CD150) [46] and might be useful in fur-
her distinction between T-regulatory cells and allo-
eactive cells in the donor cell pool.
The role of CD4 CD25 T-regulatory cells in
uppressing alloreactivity is increasingly being recog-
ized, and the loss of such cells from the donor pool
ight result in increased GVHD. Loss of T-regula-
ory function is seen in individuals with autoimmune
nd atopic conditions [47]. Nonselective T-cell deple-
ion leads to disordered immune reconstitution and
he loss of hierarchical control, which may be mani-
ested as autoimmune disorders such as autoimmune
emolytic anemia [48].
Selective allodepletion based on the upregulation
f CD25 will remove or destroy not only alloreactive
ells that have upregulated CD25 on allostimulation,
ut also any cells that express CD25 constitutively,
B&MTncluding CD4 CD25 T-regulatory cells: such
echniques will therefore deplete the donor T-cell
ool of the T-regulatory compartment with the po-
ential of increased alloreactivity and disordered im-
une reconstitution.
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